TROP2
Assets acting on this target.
- Class
- TROP2-directed
- Pathway
- TROP2-targeted delivery of monomethyl auristatin E cytotoxic payload to tumor cells
TROP2 (trophoblast cell-surface antigen 2) is a transmembrane glycoprotein expressed at low levels on many normal epithelial tissues but markedly overexpressed on the surface of numerous solid tumors, including cancers of the breast, lung, bladder, and gastrointestinal tract. Because of this differential expression, TROP2 serves less as a driver of tumor growth to be blocked and more as a docking point for targeted drug delivery. Antibody-drug conjugates (ADCs) exploit this by linking a monoclonal antibody that recognizes TROP2 to a cytotoxic payload, in this case monomethyl auristatin E (MMAE), a potent inhibitor of microtubule assembly. Upon binding, the antibody-payload complex is internalized by the tumor cell, and the payload is released intracellularly, causing cell-cycle arrest and death. This strategy aims to concentrate a highly toxic chemotherapeutic agent within tumor tissue while limiting systemic exposure, broadening the therapeutic window compared with administering the cytotoxic agent alone. TROP2-directed ADCs are being explored across a wide range of epithelial malignancies where the antigen is commonly overexpressed, reflecting a strategy of using tumor-selective surface markers as delivery vehicles rather than as direct signaling targets whose inhibition alone would be expected to slow tumor growth.
By indication
Related mechanisms
TROP2 drugs compared
8 drugs, stage by indication
| Drug | Developer | Modality | Furthest stage | Stage by indication |
|---|---|---|---|---|
| Datopotamab Deruxtecan | AstraZeneca, Daiichi Sankyo | antibody-drug conjugate | Approved | Approved in Breast Cancer; Approved in HR+/HER2- Metastatic Breast Cancer; Approved in Non-Small Cell Lung Cancer; Phase 3 in Urothelial Carcinoma |
| Sacituzumab Govitecan | Gilead Sciences | antibody-drug conjugate | Approved | Approved in Breast Cancer; Approved in HR+/HER2- Metastatic Breast Cancer; Phase 3 in Endometrial Cancer; Phase 3 in Non-Small Cell Lung Cancer; Phase 3 in Urothelial Carcinoma |
| Sacituzumab Tirumotecan | Merck & Co., Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | antibody-drug conjugate | Phase 3 | Phase 3 in Bladder Cancer; Phase 3 in Breast Cancer; Phase 3 in Cervical Cancer; Phase 3 in Endometrial Cancer; Phase 3 in HR+/HER2- Metastatic Breast Cancer; Phase 3 in Non-Small Cell Lung Cancer; Phase 3 in Ovarian Cancer |
| Sacituzumab drozuntecan | BioNTech, DualityBio Inc. | antibody-drug conjugate | Phase 2 | Not recorded |
| Tizetatug rezetecan | Jiangsu Hengrui Pharmaceuticals | antibody-drug conjugate | Phase 2 | Phase 2 in Non-Small Cell Lung Cancer |
| BL-M02D1 | Sichuan Baili Pharmaceutical | antibody-drug conjugate | Phase 1/2 | Phase 1/2 in Non-Small Cell Lung Cancer |
| LCB84 | Janssen, LigaChem Biosciences, Inc. | antibody-drug conjugate | Phase 1/2 | Not recorded |
| MT-302 | CREATE Medicines | gene therapy | Phase 1 | Not recorded |